The Medicines and Healthcare products Regulatory Agency (MHRA) has approved olezarsen (brand name Tryngolza) for adults with familial chylomicronemia syndrome (FCS), confirming the decision on 10 April 2026. The regulator describes FCS as a condition that can drive very high triglycerides and life‑threatening pancreatitis. (gov.uk)
FCS is a rare, inherited lipid disorder marked by persistent chylomicronaemia and extreme triglyceride elevations, with recurrent abdominal pain and acute pancreatitis as hallmark risks. NICE’s earlier highly specialised technology guidance for volanesorsen estimated that around 80 to 100 people in the UK might be eligible for treatment, underscoring the very small patient population. (nice.org.uk)
According to the MHRA announcement, olezarsen is administered as a subcutaneous injection, typically into the abdomen, front of the thighs or back of the upper arms. Full dosing and administration particulars for the UK will be set out in the Summary of Product Characteristics (SmPC) due to be published within seven days of approval. (gov.uk)
Efficacy was demonstrated in a 66‑patient trial in adults with FCS, where all participants followed a controlled diet and received either Tryngolza or placebo. At six months, triglycerides fell by an average of 32% with Tryngolza compared with a 12% average increase on placebo; this effect was maintained and improved at one year, with fewer acute pancreatitis events reported in the active arm. (ema.europa.eu)
The European Medicines Agency classifies Tryngolza as an antisense oligonucleotide designed to inhibit hepatic production of apolipoprotein C‑III (apoC‑III), thereby lowering triglyceride levels. The medicine holds an EU marketing authorisation, granted on 17 September 2025. (ema.europa.eu)
The approval in the UK was granted via the International Recognition Procedure (IRP) Route B. Under IRP, the MHRA can take account of assessments by trusted “reference regulators” such as the EMA or FDA. Route B operates to a 110‑day timetable and is used where additional UK assessment may be required, for example for new active substances or where the risk management plan or environmental risk assessment needs UK consideration. (gov.uk)
Recognition B also allows for consultation with the Commission on Human Medicines (CHM) if necessary and includes a single clock‑stop to address outstanding issues. Route selection is determined through a pre‑submission eligibility process conducted six weeks before filing. (gov.uk)
The marketing authorisation holder named by the MHRA is Swedish Orphan Biovitrum AB (publ). Sobi has stated it holds exclusive commercial rights to Tryngolza in territories outside the United States (excluding Canada and China), aligning responsibility for UK supply and post‑authorisation obligations with the company. (gov.uk)
Safety monitoring will follow standard UK pharmacovigilance processes. The MHRA has confirmed it will continue to review the safety and effectiveness of olezarsen as use expands, and healthcare professionals and patients are asked to report suspected adverse reactions through the Yellow Card scheme. (gov.uk)
For clinicians and service planners, today’s decision signals a potential shift in FCS management for a very small cohort. Existing NICE guidance on volanesorsen provides context on patient numbers and care pathways; routine commissioning and pricing decisions for olezarsen will be shaped by subsequent UK product information and any future health technology assessment. (nice.org.uk)